Effect of aerobic training and omega-3 exercise on oxidative and inflammatory elements in obese women

Effects of aerobic training and omega-3 supplementation on the levels of Paraoxonase, myeloperoxidase and some inflammatory and oxidative markers in overweight and obese women’s

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200722048167N1

Enrollment

Registered

2020-08-08

Start date

2020-05-04

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and obesity. Obesity due to excess calories

Interventions

Intervention 1: Intervention group: Omega 3 supplement group (taking omega 3 supplement, not participating in aerobic exercise program):for 8 weeks and daily 2000 mg of omega 3 fatty acid supplement

Eligibility

Sex/Gender

Female

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age range 25 to 40 years; Physical health; Subjects' body mass index more than 25 kg / m2 and less than 35 kg / m2; Ability to participate in aerobic exercise program; Not participating in regular exercise for the past year; No diagnosed diseases such as diabetes, cardiovascular, cancer, gastrointestinal diseases, liver, kidney, autoimmune diseases, inflammation, thyroid, polycystic ovary syndrome; Do not take antihypertensive drugs or lipid-lowering drugs; Do not take nutritional supplements for at least six months before the study.

Exclusion criteria

Exclusion criteria: No signing informed consent Smoking or drinking alcohol at least once a week Use of contraceptives and nonsteroidal anti-inflammatory drugs (NSAIDs) in the last 3 months Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Paraoxonase 1. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;Myeloperoxidase. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;Apolipoprotein A1. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;Apolipoprotein B. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;C-Reactive Protein. Timepoint: First, the end of the study. Method of measurement: Bionic Kit.	—

Measure

Time frame

Paraoxonase 1. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;Myeloperoxidase. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;Apolipoprotein A1. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;Apolipoprotein B. Timepoint: First, the end of the study. Method of measurement: ELISA Kit.;C-Reactive Protein. Timepoint: First, the end of the study. Method of measurement: Bionic Kit.

—

Secondary

Measure	Time frame
Blood Suger. Timepoint: First, the end of the study. Method of measurement: Glucose Test Kit.;Insulin. Timepoint: First, the end of the study. Method of measurement: Insulin ELISA Kit.;VO2 max. Timepoint: First, the end of the study. Method of measurement: Rockport test and formula method.;Body Mass Index. Timepoint: First, the end of the study. Method of measurement: Twice the height / weight.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShila Montazer

Islamic Azad University

shilamontazer@gmail.com+98 34 3245 3916

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026